Core Viewpoint - Rongchang Biopharmaceutical (688331.SH) has received approval from the National Medical Products Administration for the clinical trial of its dual-target ADC drug RC288, aimed at treating locally advanced unresectable or metastatic malignant solid tumors in Phase I/IIa trials [1] Group 1: Drug Development - RC288 is a dual-specific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA (Prostate-Specific Membrane Antigen) is a type II transmembrane glycoprotein that supports tumor growth and angiogenesis [1] - B7H3 is an immune checkpoint molecule that, when overexpressed in tumors, promotes immune evasion and tumor progression [1] Group 2: Market Potential - Both PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and newly formed tumor blood vessels, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]

Core Viewpoint - Rongchang Biopharma has received approval from the National Medical Products Administration for its self-developed dual-target ADC drug RC288, which is intended for the treatment of locally advanced unresectable or metastatic malignant solid tumors in a Phase I/IIa clinical trial [1] Group 1: Drug Development - RC288 is a bispecific ADC that targets both PSMA and B7H3, developed using next-generation conjugation and toxin technology [1] - PSMA and B7H3 are highly promising therapeutic targets, expressed in various malignant tumor tissues and tumor neovascularization, and are involved in tumor proliferation, invasion, and drug resistance signaling pathways [1]